Law360, New York (January 26, 2006, 12:00 AM ET) -- Less than one year after India, one of the world’s leading suppliers of generic drugs, passed a controversial measure intended to bring the country's patent regime into line with international standards, its top generics makers are under pressure to compete in a cutthroat worldwide market.
Indian pharmaceutical companies such as Ranbaxy, Dr. Reddy's Labs, Cipla, Wockhardt, and Sun Pharma are continuing to challenge patents overseas and to seek contracts as suppliers of drug ingredients for pharmaceutical companies.
Ranbaxy, for one, has pending litigation attacking major drugs...
Curbed At Home, India's Generic Makers Go Overseas
To view the full article, take a free trial now.
